Clinical Trials Logo

Clinical Trial Summary

This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03678688
Study type Interventional
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date October 18, 2018
Completion date March 11, 2022

See also
  Status Clinical Trial Phase
Completed NCT00933790 - Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis Phase 3
Completed NCT04645836 - Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'. N/A
Recruiting NCT06058299 - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis Phase 2
Completed NCT03722472 - Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults Phase 1
Completed NCT00212550 - Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb N/A
Recruiting NCT03025516 - Performance Evaluation of TB Breath- and Cough-testing Platforms N/A
Completed NCT02961569 - Comparison Between Two Strategies for the Diagnosis of TB N/A
Recruiting NCT05426720 - Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
Recruiting NCT04264221 - Promoting Overall Care and Management Related to Tuberculosis Infection Through Pharmaceutical Care and Text Messaging N/A
Active, not recruiting NCT05221502 - Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB Phase 2